Posters presented at the American Heart Association (AHA) Scientific Sessions 2026 described cardiovascular risks associated with cannabis use and caffeine-containing beverages and other products.
Niti Dalal, MD, and Aabha Divya, MBBS, co- authored a poster (Mo3041) describing past-30-day cannabis use frequency and prevalent atherosclerotic cardiovascular disease (ASCVD), including myocardial infarction (MI), coronary heart disease (CHD)/angina, or stroke, from 2020 to 2024 among US adults who responded to telephone surveys for the Behavioral Risk Factor Surveillance System (BRFSS).
Among 442,906 adults, adjusting for other risk factors, including tobacco smoking, alcohol use, obesity, and diabetes, cannabis use was associated with higher ASCVD odds in key subgroups, including never-smokers, women, and young adults. The strongest link between cannabis use and CVD was with stroke. These findings support incorporating cannabis exposure into cardiovascular risk assessment and counseling of possible stroke risk.
Efe Saglam, MD, and colleagues reported (Poster Mo3048) on changes in cardiac conduction parameters associated with current cannabis smoking and tetrahydrocannabinol (THC) edible consumption. This study analyzed a retrospective cohort database at UCSF Medical Center (March 2018-December 2024; N=782, including 392 current users, 195 non-users, and 166 prior users).
Current cannabis/THC use was associated with a statistically significantly shorter PR interval on electrocardiogram, independent of measured ventricular rate, in women, and in adults age ≥65, especially after excluding atrial fibrillation(AF) and heart failure (HF). These findings warrant prospective studies quantifying exposure.
Sathwik Billa presented a poster (Sa3065) on cannabis use and risk of pericarditis and myocarditis in adults aged 18-50 years with and without cannabis use identified using the TriNetX US Collaborative Network.
Cohorts were propensity-matched 1:1 on demographics, hypertension, diabetes, obesity, chronic kidney disease, lipid disorders, nicotine dependence, alcohol use, tobacco use, and COVID-19.
Cannabis use was associated with new-onset pericarditis/myocarditis at 1 year (88 vs 30 events) and 3 years (168 vs 56). Both components were independently significant at 3 years. Cannabis was also associated with pericardial effusion, AF, and HF at 3 years. The association persisted after accounting for smoking, other substances, and mental health. The authors concluded that residual confounding cannot be excluded, warranting prospective studies.
Sai Samayamanthula presented an analysis of the cardiovascular safety of caffeine- and stimulant-containing beverages and supplements (Poster MDP0323). He and colleagues analyzed the FDA CFSAN Adverse Event Reporting System (CAERS), obtaining 28,345 unique reports from 2017 to 2025 on serious heart conditions associated with consumption of products containing caffeine, methylxanthines, and sympathomimetics.
Caffeine- and stimulant-containing beverages and supplements were associated with more acute cardiovascular events, including cardiac arrest, MI, and ventricular arrhythmia (11, 4.5, and 4 times more likely, respectively) than for products not containing their ingredients. Almost half the events occurred in adults aged 18 to 34 years.
Study limitations include the voluntary nature of CAERS report, and the unknown number of exposed consumers or time between consumption and AE. Dr. Gregory Marcus, chair of AHA’s scientific statement on caffeine and cardiovascular disease said that more research is needed to determine whether these products are responsible for the reported events.



